NKMax
OverviewSuggest Edit
NKMax America is a company developing cellular therapies that use the power of a patient’s immune system. It helps people with cancer, autoimmune disease, and neurodegeneration.
| Type | Private | |
| Founded | 2017 | |
| HQ | Santa Ana, CA, US | Map |
| Website | nkgenbiotech.com |
Recent NewsAll News
- NKMax Announces SNK01 Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting
- NKMax and Merck KGaA, Darmstadt, Germany Expand Clinical Collaboration to Include Phase I/IIa Trial Investigating the Combination of SNK01 with ERBITUX® (cetuximab) in Metastatic NSCLC
- NKMax America Announces Corporate Name Change to NKGen Biotech
- Affimed and NKMax America Announce FDA Clearance of IND Application to Study the Combination of AFM24, an EGFR Targeted Innate Cell Engager, with SNK-01 Natural Killer Cell Therapy in Solid Tumors
Latest Updates
| Employees (est.) (Nov 2021) | 65 | |
| Cybersecurity rating | B | More |
Key People/Management at NKMax
Stephen Chen
Chief Operating Officer, Chief Technical Officer
Yongman Kim
Chief Scientific Officer, Chief Innovation Officer
Will de Groot
Chief Business Officer
Kim Beaudette
Director, Human Resources
Lucia Hui
Director, Clinical Laboratory Operations
Yoonmi Kang
Assistant Director, Manufacturing
NKMax Office Locations
NKMax has an office in Santa Ana
Santa Ana, CA, US (HQ)
3001 Daimler St
NKMax Financials and Metrics
Summary Metrics
Founding Date | 2017 |
NKMax total Funding | $11 m |
NKMax latest funding size | $11 m |
Time since last funding | 2 years ago |
NKMax's latest funding round in December 2019 was reported to be $11 m. In total, NKMax has raised $11 m
NKMax Cybersecurity Score
NKMax Online and Social Media Presence
NKMax's Trends
NKMax News and Updates
October 04, 2021
NKMax Announces SNK01 Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting
SANTA ANA, Calif., Oct. 04, 2021 (GLOBE NEWSWIRE) -- NKMax, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell therapies, today announced that an abstract highlighting key data from a Phase I SNK01 study in Non-Small Cell Lu…
April 13, 2021
NKMax and Merck KGaA, Darmstadt, Germany Expand Clinical Collaboration to Include Phase I/IIa Trial Investigating the Combination of SNK01 with ERBITUX® (cetuximab) in Metastatic NSCLC
SEOUL, South Korea, April 13, 2021 (GLOBE NEWSWIRE) -- NKMax, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell therapies, announced the expansion of its clinical trial and supply agreement with Merck KGaA, Darmstadt, Germa…
April 02, 2021
NKMax America Announces Corporate Name Change to NKGen Biotech
SANTA ANA, Calif., April 02, 2021 (GLOBE NEWSWIRE) -- NKMax America, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell therapies, today announced that it has changed its corporate name to NKGen Biotech, Inc., which the Comp…
March 31, 2021
Affimed and NKMax America Announce FDA Clearance of IND Application to Study the Combination of AFM24, an EGFR Targeted Innate Cell Engager, with SNK-01 Natural Killer Cell Therapy in Solid Tumors
Heidelberg, Germany and Santa Ana, Calif., March 31, 2021 - Affimed N.V. (NASDAQ: AFMD), a clinical-stage immuno-oncology company, and NKMax America Inc., a clinical stage biotech company, announced today that the U.S. Food and Drug Administration (FDA) cleared an investigational new drug applicatio…
February 04, 2021
NKMax America Announces Key Leadership Appointment
SANTA ANA, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) -- NKMax America, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell therapies, announced the appointment of Stephen Chen, MBA to Chief Operating Officer (COO).
October 20, 2020
Affimed and NKMax America to Study the Combination of AFM24, an EGFR-Targeted Innate Cell Engager, with SNK01 Natural Killer Cell Therapy
HEIDELBERG, Germany and SANTA ANA, Calif., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ: AFMD) and NKMax America Inc., both clinical stage biotech companies focused on harnessing the power of the body’s innate immune system, announced today that they entered into a clinical collaboration…
NKMax Frequently Asked Questions
When was NKMax founded?
NKMax was founded in 2017.
Who are NKMax key executives?
NKMax's key executives are Stephen Chen, Yongman Kim and Will de Groot.
How many employees does NKMax have?
NKMax has 65 employees.
Who are NKMax competitors?
Competitors of NKMax include Alector, Neovii and Eutilex.
Where is NKMax headquarters?
NKMax headquarters is located at 3001 Daimler St, Santa Ana.
Where are NKMax offices?
NKMax has an office in Santa Ana.
How many offices does NKMax have?
NKMax has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies